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Objectives: The whole genomes of two Acinetobacter baumannii isolates recovered from a 22 
single patient were sequenced to gain insight into the nature and extent of genomic plasticity in 23 
this important nosocomial pathogen over the course of a short infection. The first, AB210, was 24 
recovered before tigecycline therapy and was susceptible to this agent; the second, AB211, was 25 
recovered after therapy and was resistant.  26 
Methods: DNA from AB210 was sequenced by 454 GS FLX pyrosequencing according to 27 
the standard protocol for whole-genome shotgun sequencing, producing ~250-bp fragment reads. 28 
AB211 was shotgun-sequenced using the Illumina Genetic Analyzer to produce fragment reads 29 
of exactly 36-bp. Single nucleotide polymorphisms (SNPs) and large deletions detected in 30 
AB211 in relation to AB210 were confirmed by PCR and DNA sequencing. 31 
Results: Automated gene-prediction detected 3,850 putative coding sequences (CDS). 32 
Sequence analysis demonstrated the presence of plasmids pAB0057 and pACICU2 in both 33 
isolates. Eighteen putative SNPs were detected between the pre- and post-therapy isolates, 34 
AB210 and AB211. Three contigs in AB210 were not covered by reads in AB211, representing 35 
three deletions of approximately 15, 44 and 17 kb.  36 
Conclusions: This study demonstrates that significant differences were detectable between two 37 
bacterial isolates recovered one week apart from the same patient, and reveals the potential of 38 
whole-genome sequencing as a tool for elucidating the processes responsible for changes in 39 
antibiotic susceptibility profiles. 40 
 41 
 42 
Introduction  43 
Acinetobacter baumannii is an important nosocomial pathogen, with multidrug-resistant (MDR) 44 
and even pan-drug-resistant strains reported world-wide.
1 
In the UK, carbapenem-resistant clonal 45 
lineages limit available treatment options. One successful lineage, designated OXA-23 clone 1, 46 
belonging to European clone II, has been recovered from over 60 hospitals, clustered mainly in 47 
London and South-East England.
2
 Representative isolates of this clone are usually susceptible to 48 
colistin and tigecycline only. We previously reported the emergence of tigecycline resistance 49 
during antibiotic therapy in the OXA-23 clone 1 epidemic lineage, and showed that increased 50 
expression of the resistance-nodulation-division (RND) efflux system, AdeABC was responsible 51 
for the resistance phenotype.
3
 52 
 The recent availability of rapid and inexpensive whole-genome sequencing permits 53 
detailed investigation of genetic differences between pairs of bacterial isolates. In A. baumannii 54 
whole-genome studies have thus far focused either on comparing distinct antibiotic-susceptible 55 
and MDR strains,
4,5
 or related isolates from different patients.
6
 The results of these and other 56 
similar studies
7
 point to a high degree of genome plasticity, the rapid emergence of antibiotic 57 
resistance, and considerable genetic variability even among closely-related isolates.  58 
Tigecycline is used as a treatment of last resort for MDR A. baumannii infection, despite 59 
a lack of formal trial data and the emergence of resistance is a major concern. We sequenced the 60 
genomes of two A. baumannii isolates from a single patient, the first recovered before tigecycline 61 
therapy and susceptible to this agent, the second after one week of therapy for an intra-abdominal 62 
infection and resistant. The study aimed to gain insight into the nature and extent of genomic 63 
plasticity over the course of a short infection. 64 
Materials and Methods  65 
Bacterial isolates  66 
Clinical isolates AB210 and AB211 have been described previously.
3
 As OXA-23 clone 1 67 
representatives, they belong to the globally successful European clone II group, and were 68 
assigned to Group 1 by the multiplex PCR method described by Turton et al.
8
 They were typed 69 
by PFGE of ApaI-digested genomic DNA (Figure 1), as described previously,
2
 and the presence 70 
of blaOXA-23-like was confirmed by multiplex PCR.
9
 71 
Antimicrobial susceptibility testing and DNA manipulations 72 
MICs were determined by BSAC agar dilution or Etest (AB bioMérieux, Solna, Sweden) on 73 
IsoSensitest agar (Oxiod, Basingstoke, UK) with the results interpreted according to BSAC 74 
guidelines.
9
 Genomic DNA was extracted with the Wizard Genomic DNA Purification Kit 75 
(Promega, Southampton, UK) and was used as template for DNA sequencing. Plasmids were 76 
isolated from AB210 and AB211 using the PureYield Plasmid Miniprep System (Promega) and 77 
analysed by agarose gel electrophoresis. 78 
Whole-genome DNA sequencing and data analysis 79 
DNA from AB210 was sequenced by 454 GS FLX pyrosequencing (Roche, Branford, 80 
Connecticut, USA) according to the standard protocol for whole-genome shotgun sequencing, 81 
producing ~250 bp fragment reads. AB211 was shotgun sequenced using the Illumina Genetic 82 
Analyzer (Illumina, Saffron Walden, UK) to produce fragment reads of exactly 36-bp. All 83 
sequencing was performed at GATC Biotech Ltd (Constance, Germany). A draft genome 84 
assembly for AB210 was produced from flowgram data, using Newbler 2.5 (Roche). The 85 
Newbler command-line option ‘-rip’ was used to ensure reads were aligned to single contigs 86 
only. The resulting contigs were annotated by reference to the related strain A. baumannii 87 
ACICU
10
 (also belonging to European clone II) using the automated annotation pipeline on the 88 
xBASE server.
11
  89 
Illumina reads for isolate AB211 were mapped against the draft AB210 assembly using 90 
Bowtie 0.12.0.
12
 For the purposes of single nucleotide polymorphism (SNP) detection, Bowtie 91 
was run with parameter ‘-m 0’ to suppress alignments that map equally to multiple locations in 92 
the genome.  To detect deletions this setting was not used. A consensus pileup was produced 93 
using SAMtools,
13
 and putative SNPs were called using Varscan 2.2
14
 with the following 94 
parameters: minimum coverage (10), min-reads2 (2), min-avg-qual (15), min-var-freq (0.9). To 95 
detect microindels (insertion or deletion events) less than 3-bases long, AB211 reads were 96 
additionally mapped using Novoalign 2.5.
15
 Whole-genome alignments were visualised and 97 
SNPs and deletions manually inspected using the output files from the above steps using 98 
BAMview. 
16
 99 
Confirmation of SNPs and chromosomal deletions 100 
SNPs and deletions detected in AB211 in relation to AB210 were confirmed by PCR and DNA 101 
sequencing using the primers listed in Table S1. Nucleotide sequences of the resulting amplicons 102 
were determined with an ABI 3730xl DNA analyser (Applied Biosystems, Warrington, UK).  103 
 104 
 105 
 106 
 107 
Results & Discussion 108 
Antibiotic susceptibilities  109 
MICs of tigecycline, tobramycin, amikacin, gentamicin and azithromycin for the pre-therapy 110 
isolate AB210 were 0.5, >32, >64, >32 and >256 mg/L, respectively, while MICs for the post-111 
therapy isolate AB211 were 16, 2, 4, 8 and >256 mg/L, respectively.   112 
Sequencing results 113 
Sequencing produced >128 million and >156 million sequence reads for AB210 and AB211, 114 
respectively. The assembly of AB210 resulted in 91 contigs larger than 500-bp, comprising 4.06 115 
megabases of sequence and representing a median 29-fold coverage. Automated gene-prediction 116 
detected 3,850 putative coding sequences (CDS), of which 3,504 were homologous (defined as 117 
BLASTP e-value ≤ 1e-05) to a sequence in the reference genome of A. baumannii ACICU. The 118 
vast majority (96.6 %) of the AB211 reads mapped to a region on the AB210 genome. The 119 
AB210 draft assembly has been deposited in GenBank (accession number: AEOX00000000) and 120 
raw sequence reads for AB210 and AB211 have been submitted to NCBI’s Sequence Read 121 
Archive under Study Accession Number SRP004860. 122 
Plasmid profile 123 
Plasmid profiles of AB210 and AB211 were identical and showed the presence of two plasmids 124 
in each isolate (data not shown). Sequence analysis demonstrated the presence of a 9-kb contig in 125 
AB210 which displayed 99.98 % identity to the previously characterised pAB0057 plasmid.
5  
126 
This was seen at high sequence read coverage in both AB210 and AB211, suggesting it was 127 
present as multiple copies. Three other contigs, totalling 65 kb, were seen at below-average 128 
coverage; taken together these were a full match in length and nucleotide identity to the complete 129 
pACICU2
 
plasmid.
10 
130 
AB210 virulence genes and resistance islands 131 
Resistance islands (RIs) have been detected in all sequenced A. baumannii genomes containing 132 
multiple resistance determinants. They are composite transposons that are complex in nature and 133 
which have been designated AbaR (A. baumannii resistance).
4
 They share a common insertion 134 
site (comM) but vary considerably among isolates in terms of the exact genetic composition, with 135 
that from ACICU, a representative of European clone II being considerably reduced in size 136 
compared to those found in representatives of European clone I.
10,17
 Clinical isolates AB210 and 137 
AB211 were found to contain an AbaR-type RI. In the former isolate (GenBank accession 138 
number HQ700358) this was shown to contain sequence corresponding to nucleotides 587330-139 
599047 of strain AB0057 (GenBank accession number CP001182), with a 2.85 kb section 140 
absent; this is an AbaR4-type island, and contains blaOXA-23.  141 
 142 
SNPs between AB210 and AB211 143 
Eighteen putative SNPs were detected between the pre- and post-therapy isolates. Only one of 144 
these was located outside of coding regions at -35 bp upstream of ureJ which encodes a 145 
hydrogenase/urease accessory protein (AB210 locus tag: AB210-1_2203). The location of this 146 
SNP suggests the possibility of regulatory significance although ureJ appears to be part of a 147 
urease gene cluster which is co-transcribed as an operon in other species.
18
 Of the remaining 17, 148 
eight were synonymous mutations whereas nine were non-synonymous including one missense 149 
mutation (Table 1). Seventeen (94 %) of the SNPs were transitions. Eight of the nine non-150 
synonymous SNPs could be confirmed by PCR and sequencing while one was not validated 151 
(Table 1 and Table S1). Several of these were located within genes predicted to be involved in 152 
core biological functions, including translation (dusB), nucleic acid biosynthesis, α-ketoglutarate 153 
and arabinose transport, environmental sensing (the signal transduction histidine kinase gene, 154 
adeS which had previously been identified through a candidate-gene approach
3
), and signalling. 155 
The mutation in adeS is believed to be responsible for up-regulation of the AdeABC efflux 156 
system and hence tigecycline resistance. Two SNPs were located within a gene coding for a 157 
GGDEF domain-containing protein, one of which was a non-synonymous mutation whilst the 158 
other introduced an internal stop codon, thus giving rise to a truncated product (Table 1). These 159 
proteins are enzymes that catalyze the synthesis of cyclic-di-GMP, which has been recognized 160 
recently as an important second messenger in bacteria and is implicated in adhesin and 161 
extrapolysaccharide biosynthesis.
19
  162 
Large structural changes in the genomes of AB210 and AB211 163 
Three contigs in AB210 were not covered by reads in AB211, these putative deletions were 164 
designated ROD1, 2 and 3. The first, ROD1, was approximately 15 kb in length. This deletion 165 
disrupted the coding sequence of the DNA mismatch repair gene mutS (AB210-1_2445) by 166 
eliminating the N-terminal mutS-I domain. Aside from encoding this mismatch recognition 167 
enzyme, ROD1 also encoded a DMT superfamily permease (AB210-1_2447) and an MFS 168 
permease (AB210-1_2451), transcriptional regulators (AB210-1_2450; AB210-1_2453), an EAL 169 
domain-containing protein (AB210-1_2448), responsible for the degradation of cyclic-di-GMP.
19 
170 
At approximately 44 kb ROD2 was the largest deleted region and comprised of genes encoding 171 
for transcriptional regulators (AB210-1_3253; AB210-1_3262; AB210-1_3269; AB210-172 
1_3273), ion channels and transporters (AB210-1_3254; AB210-1_3259; [AB210-1_3275; 173 
AB210-1_3276; AB210-1_3277]), a class A β-lactamase enzyme (AB210-1_3248) and 174 
components of a type VI secretion system (AB210-1_3280; AB210-1_3281).
20
 Interestingly, part 175 
of the type VI secretion locus was missing even in AB210, suggesting that this was a degenerate 176 
system in both isolates. ROD1 and ROD2 are contiguous in A. baumannii ACICU, suggesting 177 
this may be a single deletion, but this could not be confirmed experimentally for AB210 by PCR 178 
(data not shown). ROD3, approximately 17 kb in length, included a class 1 integron containing 179 
antibiotic resistance genes including macrolide resistance determinants (AB210-1_3691 180 
[phosphotransferase]; AB210-1_3692 [an efflux protein]) and several genes encoding 181 
aminoglycoside resistance determinants, namely aac(6')-Ib (AB210-1_3701), two copies of 182 
aadA (AB210-1_3699; AB210-1_3700) and armA (AB210-1_3695), which encodes a 16S rRNA 183 
methylase.  184 
 185 
Implications for Acinetobacter evolution 186 
The extent of genomic changes detected here are consistent with the marked changes in 187 
phenotype, particularly the loss of aminoglycoside resistance in AB211. However, we were 188 
unable to determine whether these changes were the result of rapid evolution during the course 189 
of infection and treatment, or whether the patient initially had a mixed infection (or re-infection), 190 
involving different variants of the same defined clone, with subsequent selection for tigecycline 191 
resistance.    192 
The disruption of mutS, an important DNA mismatch repair gene, is significant and 193 
suggests the possibility of a hypermutator phenotype, which may have contributed to the 194 
relatively large number of SNPs. Previous work in Acinetobacter sp. ADP1 has shown that mutS 195 
preferentially recognises and repairs transitions,
21
 so its disruption in AB211 is consistent with 196 
our observation that 94 % of the SNPs belonged to this class. 197 
The absence of ROD3 is consistent with the change in aminoglycoside resistance 198 
between AB210 and AB211, with MICs of tobramycin, amikacin and gentamicin reduced at 199 
least 8-fold in AB211. It is notable that the development of tigecycline resistance was 200 
accompanied by increased susceptibility to other antibiotics through a large genomic deletion. 201 
GGDEF and EAL-containing proteins have been implicated in sessile to planktonic 202 
shifts. Taken together, the termination in a GGDEF domain-containing protein as well as the loss 203 
of an EAL-domain containing protein in ROD1 may be advantageous during the process of 204 
infection though this remains to experimentally determined.  205 
In this study, whole-genome sequencing gave insight into the nature of genetic changes 206 
between isolates under selection pressure through antibiotic therapy and a hostile host 207 
environment. This study has demonstrated significant differences between two A. baumannii 208 
isolates belonging to the same epidemic lineage, collected one week apart from the same patient. 209 
Such studies are able to shed light on the relative importance of SNPs and transposon 210 
mutagenesis on the evolution of A. baumannii and can generate hypotheses into the nature of 211 
antibiotic resistance and virulence. Although further studies are needed to assess the extent of 212 
genetic diversity among populations of A. baumannii in a single patient, we clearly demonstrated 213 
the potential of whole-genome sequencing as an important tool for helping elucidate the 214 
evolutionary processes responsible for the rapid development of antibiotic resistance in this 215 
important nosocomial pathogen. 216 
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Table 1. Confirmed SNPs indentified in clinical isolate AB211 resulting in amino acid substitution or termination 
SNP 
Position in 
AB210 
assembly 
Locus tag in 
AB210 assembly 
Protein product 
Amino acid identity 
Orthologue 
AB210 AB211 
1 159509 AB210-1_0138 tRNA-dihydrouridine synthase, DusB A T ABAYE0965 
2 639321 AB210-1_0587 nucleoside-diphosphate-sugar epimerase T A ACICU_01645 
3 755474 AB210-1_0703 major facilitator superfamily permease V A ACICU_01760 
4 1469178 AB210-1_1405 hypothetical protein A V ACICU_02205 
5 2548057 AB210-1_2423 major facilitator superfamily permease A T ACICU_01217 
6 2852737 AB210-1_2721 Signal transduction histidine kinase, AdeS A V ACICU_01827 
7 3362158 AB210-1_3207 GGDEF domain-containing protein Q * ACICU_03492 
8 3362175 AB210-1_3207 GGDEF domain-containing protein G V ACICU_03492 
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Figure Legands 
Figure 1. PFGE profiles of AB210 (lane 2) and AB211 (lane 3).  
 
